Trial Profile
A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 02 May 2019 Results published in the CNS Drugs
- 16 May 2016 Status changed from recruiting to completed.
- 29 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as per ClinicalTrials.gov record.